Short Interest in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Increases By 3,584.7%

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a large increase in short interest in June. As of June 15th, there was short interest totaling 942,551 shares, an increase of 3,584.7% from the May 31st total of 25,580 shares. Based on an average trading volume of 28,446,970 shares, the days-to-cover ratio is currently 0.0 days. Approximately 79.8% of the shares of the stock are short sold.

Institutional Trading of Regentis Biomaterials

An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new position in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials as of its most recent SEC filing.

Regentis Biomaterials Price Performance

NYSEAMERICAN:RGNT traded down $0.25 during mid-day trading on Friday, hitting $3.90. 226,070 shares of the company’s stock were exchanged, compared to its average volume of 16,508,901. Regentis Biomaterials has a fifty-two week low of $1.23 and a fifty-two week high of $15.50. The stock’s 50 day moving average is $2.80.

Analyst Ratings Changes

Separately, ThinkEquity upgraded Regentis Biomaterials to a “strong-buy” rating in a research report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, Regentis Biomaterials currently has an average rating of “Strong Buy”.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.